Perennial malaria chemoprevention (PMC) is newly formulated strategy endorsed in June 2022 by the World Health Organization and builds off the previously recommended but poorly implemented strategy of intermittent preventive treatment of malaria in infants – IPTi. IPTi – the provision of single dose Sulphadoxine Pyrimethamine (SP) delivered through the Expanded Program of Immunization (EPI) at times of childhood immunisation at approximately 3, 4 and 9 months of age was shown to provide infants with protection against malaria, anaemia and all cause hospital admissions.